Anti-Cancer Drug Assay for Micro-Ellipse Filters after Sensitively Capturing Circulating Tumor CellsHongmei Chen1,2*, Baoshan Cao3, Hongda Chen2, Hui Yang1, Peihua Liu1, Tengfei Wang1 and Chunfei Hu1
- *Corresponding Author:
- Hongmei Chen
Division of Nano Bionic Research, Suzhou Institute of Nano-Tech and Nano-Bionics
Chinese Academy of Sciences, Suzhou, Jiangsu, China
E-mail: [email protected]
Received Date: April 24, 2017; Accepted Date: May 08, 2017; Published Date: May 11, 2017
Citation: Chen H, Cao B, Chen H, Yang H, Liu P, et al. (2017) Anti-Cancer Drug Assay for Micro-Ellipse Filters after Sensitively Capturing Circulating Tumor Cells. J Depress Anxiety S11:002. doi:10.4172/2167-1044.S11-002
Copyright: © 2017 Chen H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Circulating tumor cells (CTCs) carrying significant information from primary tumor rendering precise enumeration valuable. Extremely rare number detected in the patient sample belongs to early stage of cancer. Detection, characterization and further molecular analysis determine prognosis and diagnosis. In this work, we performed Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) to precisely enumerate number of tumor cells captured on the highly-sensitive gradual narrowed micro-ellipse filters. Clinical assay was performed on Ellipse filters to assess further validity in non-small-cell-lung cancer (NSCLC) patient blood with CTCs detected positive. Antidrug cancer assays were performed with micro-ellipse filters after cells captured on the chip treated with baicalein (BAE) of different concentrations. Highly-sensitive micro-ellipse filters validate efficiency of clinical enumeration of metastatic patient samples, anti-cancer drug responses after improvement of co-culture design and mutational biological molecular analysis.